53P: Characterisation of benefit-risk by pemetrexed (pem) exposure in patients (pts) with EGFRm aNSCLC treated with 1L osimertinib (osi) + platinum-pem in FLAURA2

Category Primary study
ConferenceEuropean Lung Cancer Congress (ELCC) 2025
Year 2025
This article has no abstract
Epistemonikos ID: 53f8bfd63870f3ec60b798eafae2acb371343f7b
First added on: Jan 22, 2026